Ourthat OAC, aspirin, or no therapy can be considered. In contrast, the ESC guidelines 1 recommend that OAC should be considered in such a patient (Class IIa recommendation), considering patient values and preferences. OAC refers to use of a vitamin K antagonist (with good-quality anticoagulation control, as reflected by a time in therapeutic range >70%) or an nOAC. After discussion and counseling, our patient was keen on stroke prevention and was treated with an nOAC, specifically apixaban 5 mg twice daily. He discontinued aspirin.
